Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125315992 | 12531599 | 2 | F | 20151025 | 20160621 | 20160706 | 20160707 | EXP | CN-009507513-1511CHN012445 | MERCK | 39.00 | YR | M | Y | 68.00000 | KG | 20160707 | MD | CN | CN |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125315992 | 12531599 | 1 | PS | EMEND | APREPITANT | 1 | Oral | 125 MG, ONCE | 160 | MG | K010950 | 21549 | 125 | MG | CAPSULE | 1X | |||
125315992 | 12531599 | 2 | SS | EMEND | APREPITANT | 1 | Oral | 80 MG, QD | 160 | MG | 21549 | 80 | MG | CAPSULE | QD | ||||
125315992 | 12531599 | 3 | C | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous drip | 1.8 G D1,5 + CISPLATIN INJECTION 45MG D2 TO D4(TREATMENT CYCLE 1) | 0 | 1.8 | G | INJECTION | |||||||
125315992 | 12531599 | 4 | C | CISPLATIN. | CISPLATIN | 1 | Intravenous drip | GEMCITABINE INJECTION 1.8G D1, 5 + CISPLATIN INJECTIO 5 MG, DAY 2 TO DAY 4 TREATMENT CYCLE 1/UNKNOWN | 0 | 45 | MG | INJECTION | |||||||
125315992 | 12531599 | 5 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Intravenous drip | 30 MG, DAILY | 180 | MG | U | 0 | 30 | MG | INJECTION | QD | |||
125315992 | 12531599 | 6 | C | AMIFOSTINE. | AMIFOSTINE | 1 | Intravenous drip | 400 MG, DAILY | 2400 | MG | U | 0 | 400 | MG | INJECTION | QD | |||
125315992 | 12531599 | 7 | C | PALONOSETRON HYDROCHLORIDE. | PALONOSETRON HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | TOTAL DAILY DOSE: 0.25 MG (QD) | U | 0 | INJECTION | QD | |||||||
125315992 | 12531599 | 8 | C | PALONOSETRON HYDROCHLORIDE. | PALONOSETRON HYDROCHLORIDE | 1 | Intravenous drip | 0.25 MG, DAILY | U | 0 | INJECTION | QD | |||||||
125315992 | 12531599 | 9 | C | MONOSIALOGANGLIOSIDE SODIUM | 2 | Intravenous drip | 80 MG, DAILY | 480 | MG | U | 0 | 80 | MG | INJECTION | QD | ||||
125315992 | 12531599 | 10 | C | ZHEN QI FU ZHENG | 2 | Intravenous drip | 250 ML/CC, DAILY | 1500 | ML | U | 0 | 250 | ML | INJECTION | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125315992 | 12531599 | 1 | Prophylaxis of nausea and vomiting |
125315992 | 12531599 | 3 | Chemotherapy |
125315992 | 12531599 | 4 | Chemotherapy |
125315992 | 12531599 | 5 | Prophylaxis against gastrointestinal ulcer |
125315992 | 12531599 | 6 | Prophylaxis |
125315992 | 12531599 | 7 | Prophylaxis of nausea and vomiting |
125315992 | 12531599 | 8 | Allergy prophylaxis |
125315992 | 12531599 | 9 | Nervous system disorder |
125315992 | 12531599 | 10 | Supplementation therapy |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125315992 | 12531599 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125315992 | 12531599 | 1 | 20151021 | 20151021 | 0 | |
125315992 | 12531599 | 2 | 20151022 | 20151023 | 0 | |
125315992 | 12531599 | 3 | 20151020 | 20151024 | 0 | |
125315992 | 12531599 | 4 | 20151021 | 20151024 | 0 | |
125315992 | 12531599 | 5 | 20151020 | 20151026 | 0 | |
125315992 | 12531599 | 6 | 20151020 | 20151025 | 0 | |
125315992 | 12531599 | 7 | 20151020 | 20151020 | 0 | |
125315992 | 12531599 | 8 | 20151021 | 20151028 | 0 | |
125315992 | 12531599 | 9 | 20151020 | 20151026 | 0 | |
125315992 | 12531599 | 10 | 20151020 | 20151026 | 0 |